QUAGEN
GenericsQUAGEN is a generic drug manufacturer focused on Cardiovascular, Infectious Disease, Neurology.
QUAGEN's Key Drugs
QUAGEN's core commercial portfolio centers on CYPROLARA, spanning Cardiovascular and Infectious Disease — its most strategically important drugs approved in the last 15 years.
QUAGEN's Recent FDA Approvals
New NDA/BLA approvals for QUAGEN over the last two years — novel drugs only, excluding generics and label supplements.
QUAGEN's Therapeutic Areas
QUAGEN's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Infectious Disease, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
QUAGEN's Top Competitors
QUAGEN's closest competitors by therapeutic-area and drug-target overlap include Merck, Novo Nordisk, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
QUAGEN Pipeline Snapshot
Active clinical trials for QUAGEN across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • CYPROLARA leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 1942-11-10
- Latest
- 2026-10-02
- Applications
- 82